Join Mailing List   |   Jobs   |   Print Page   |   Contact Us   |   Sign In   |   Join
ISTH Webinar: Use of Novel Drugs in Hemophilia
Tell a Friend About This EventTell a Friend

When: Wednesday, August 5, 2020
13:00 UTC

« Go to Upcoming Event List  

Use of Novel Drugs in Hemophilia

August 5, 2020 13:00 - 14:00 UTC


Nicola Curry "Extended half-life replacement therapies"

Learning objectives:

By the end of the webinar participants will be familiar with:

  • the different methods for extending the half life of factor concentrates
  • the pros and cons of these treatments
  • the future role of these treatments within the landscape of haemophilia treatments 

Margaret Ragni "Non-replacement therapies"

Learning Objectives:

  • To identify the gaps and shortcomings of current factor therapies
  • To describe current approaches to manipulating the coagulation cascade to promote hemostasis 
  • To understand the mechanism, safety, and efficacy of novel non-factor therapies, emicizumab, fitusiran, and concizumab


Register Here.



Nicola Curry 

Dr. Nicola Curry is a Consultant Haematologist at the Oxford Haemophilia & Thrombosis Centre and is head of the department. Her clinical interests cover the care of patients with inherited and acquired bleeding and thrombotic disorders, including the care of women with these disorders during pregnancy. Prior to her current appointment, she was a Research Fellow at NHSBT, Oxford and completed an MD thesis in ‘The coagulopathy of trauma related haemorrhage’. Her main research interest is in the treatment of acquired coagulopathy, in particular traumatic coagulopathy and the role of early fibrinogen replacement during active major haemorrhage and she have recently secured an MRC fellowship to study the role of the endothelium in the development of coagulopathy.


Margaret V. Ragni
Dr. Ragni is a tenured Professor of Medicine and Clinical and Translational Science, Department of Medicine, Division of Hematology/ Oncology, University of Pittsburgh, and Medical Director, Hemophilia Center of Western Pennsylvania. She is actively engaged in patient care, teaching, mentoring, and federally-funded research with over 260 peer-reviewed publications in the area of hemophilia, von Willebrand disease, and thrombosis. She considers mentoring fellows and young faculty in clinical translational research to be critical to the future of benign hematology.


Supported by Instrumentation Laboratory.

Membership Management Software Powered by YourMembership  ::  Legal
This website uses cookies to store information on your computer. Some of these cookies are used for visitor analysis, others are essential to making our site function properly and improve the user experience. By using this site, you consent to the placement of these cookies. Click Accept to consent and dismiss this message or Deny to leave this website. Read our Privacy Statement for more.